Physician profile
Michael Ma
NPI 1992191571
$6,955.03
in general payments reported to CMS, 2019-2025
8 companies · $34.98 in 2025
The $34.98 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.59 · 2021: $264 · 2022: $128 · 2023: $4,270 · 2024: $2,222 · 2025: $34.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,806 · Food and Beverage: $2,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,805.77 |
| Food and Beverage | $2,720.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,389.50 | 2021-2025 | Resolution 360 Clip, Axios, Acquire |
| Micro-Tech Endoscopy USA, INC. | $431.95 | 2023-2024 | Goldknife, Repositionable Hemostasis Clip, Endorotor |
| 3-D Matrix, INC. | $377.71 | 2024 | |
| Abbvie INC. | $370.19 | 2021-2023 | |
| Madrigal Pharmaceuticals | $133.56 | 2024 | Rezdiffra |
| Qol Medical, LLC | $124.97 | 2021 | |
| Olympus America INC. | $90.56 | 2024 | Endoclot Sis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.